协同作用的HDAC4/8抑制通过pAKT/RUNX2路径调制使骨肉瘤对多克索鲁比敏感
Anuja Gajanan Magar1,2, Vivek Kumar Morya1,2, Young-Ho Koh3
1School of Medicine, Hallym University, Chuncheon-si 24252, Republic of Korea.
International journal of molecular sciences
|May 7, 2025
概括
将多克索鲁与双脱乙酶 (HDAC) 抑制剂tasquinimod和PCI-34051结合起来,通过增加亡并减少细胞迁移和化学抵抗,可以增强骨髓瘤治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓瘤是一种具有攻击性的骨癌,存活率较低,特别是在转移性病例中.
- doxorubicin (doxo) 是一种标准化疗,但由于耐药性和毒性而面临挑战.
- 基因组脱乙酶 (HDACs) 涉及化学抵抗,这表明它们是治疗点.
研究的目的:
- 调查多克索鲁比与选择性HDAC抑制剂tasquinimod (Tas) 和PCI-34051 (PCI) 在骨髓瘤中的联合治疗效果.
- 评估这种组合对细胞活力,细胞亡,迁移和关键分子通路的影响.
主要方法:
- 利用SJSA-1骨髓瘤细胞的2D和3D体外模型.
- 评估了细胞活力,细胞亡,亡和细胞迁移 (伤口愈合分析).
- 分析了包括MMP9,MMP13,pAKT,RUNX2和caspases在内的关键蛋白质的表达.
主要成果:
- 组合治疗 (doxo + Tas + PCI) 与单独使用多克索鲁比相比,显著降低了细胞活力和球状体生长.
- 增强晚期亡和亡,超过了多克索鲁比的效果.
- 抑制了37.74%的细胞迁移,并降低了MMP9/MMP13表达.
- 降低了pAKT和RUNX2的调节,同时提高了caspase 8,caspase 3和分裂的caspase 3的调节.
结论:
- 用Tas和PCI进行双重HDAC抑制可以增强多克索鲁比辛在骨髓瘤中的疗效.
- 组合疗法增强了亡,抑制了增殖,并降低了转移潜力.
- 这一策略表明,它有望克服骨髓瘤的化学抵抗,因此需要进一步研究.
关键词:
这是一种HDAC抑制剂.这是一种抗癌药物.灭症 (apoptosis) 是一种死亡的过程.组合疗法治疗组合治疗.德克索鲁比辛 (doxorubicin) 是一种药物.骨质肉瘤是骨质肉瘤的一种疾病.更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.0K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
